Slingshot members are tracking this event:
Bristol-Myers Squibb (BMY) Fails Phase 2 EkkiKIR Trial Evaluating Innate Pharma's (IPHYF) Lirilumab in Treatment of Acute Myeloid Leukemia (AML)
Slingshot Insights Explained
Feb 06, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2, Ekkikir, Lirilumab, Acute Myeloid Leukemia